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AntidepressantsElevated levels of inflammatory markers, such as C-reactive protein, are well documented in people with
depression. Few studies have examined whether the association between inflammation and depression is
symptom specific, and differs according to antidepressant treatment. Using data from the English
Longitudinal Study of Ageing (N = 5909), cross-sectional analyses revealed a significant dose-response
association between C-reactive protein and the symptoms of fatigue (P < 0.001), restless sleep
(P = 0.03), low energy (P = 0.02) and feeling depressed (P = 0.04), but not other symptoms. These associ-
ations were absent in users of anti-depressant medication. Our findings suggest the C-reactive protein-
depression association is symptom-specific and modified by antidepressant treatment.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Levels of inflammatory markers, such as C-reactive protein
(CRP), are elevated in people with symptoms of depression,
although this is not a universal observation (Valkanova et al.,
2013). In these studies, depression symptomology is commonly
measured with an aggregate score of different symptoms which
may mask symptom-specific effects (Valkanova et al., 2013).
Initial analyses into specific symptoms of depression found a
significant association between CRP levels with an increased risk
that participants reported they had ‘‘not accomplished much
recently” and felt ‘‘like giving up”, but not ‘‘often feeling nervous
or stressed” (Wium-Andersen et al., 2013). These analyses were
not, however, mutually adjusted for other symptoms, so they could
be attributed to either somatic (e.g., fatigue) or psychological
symptoms (e.g., feelings of low self-worth). In a recent item-level
analysis of the US National Health and Nutrition Examination Sur-
vey, investigators adjusted these associations for the effect of other
depressive symptoms and found CRP was independently associ-ated with somatic (e.g., reports of tiredness, lack of energy, sleep
problems and lack of appetite) but not psychological symptoms
of depression (e.g., reports of depressed mood, anhedonia, feelings
of self-worth) (Jokela et al., 2016).
We examined these relationships in the English Longitudinal
Study of Ageing (ELSA), a population of older people in whom
levels of inflammatory markers and the occurrence of depression
tend to be higher. Additionally, given that antidepressant drug
therapy can have an inflammation-lowering effect (Hannestad
et al., 2011), we explore the link between inflammation and speci-
fic symptoms of depression according to the use of such
medication.2. Materials and methods
2.1. Participants
Initiated in 2002/03 when study members were 50 years of age
or older, the ELSA is an on-going, biennial, nationally representa-
tive, multi-disciplinary prospective cohort study of older people
(Steptoe et al., 2013). Ethical approval was given by the National
Research Ethics Service (MREC/01/2/91) and written informed con-
sent obtained from all participants.er peo-
2 J. White et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxFor the present analyses, we report on data collected at wave six
(2012–2013), when blood samples for CRP and medication use
were collected by nurses (Steptoe et al., 2013). A total of 10,601
participants attended the wave six assessment, with 4476
excluded from our analysis owing to missing data on CRP, or
incomplete data on depressive symptoms, medication use, or
potential confounding or mediating factors (n = 216), resulting in
a final sample size of 5909 (mean age, 66 years; 54.9% female).
Missing values on CRP were due to exclusions placed on partici-
pants who had a clotting or bleeding disorder (e.g., haemophilia
or low platelets), those who had ever had a fit or convulsion in
the last five years, were currently taking anticoagulant drugs
(e.g., warfarin), or were unwilling to give their consent in writing
for the drawing of blood (Steptoe et al., 2013).
2.2. C-reactive protein
CRP was measured using standard procedures (median, 1.6 mg/
L; interquartile range, 0.8–3.2 mg/L) (Bridges et al., 2012) and anal-
ysed using the N Latex CRP mono Immunoassay on the Behring
Nephelometer II Analyzer (Dade Behring, Milton Keynes, UK). As
the original (Shapiro-Wilk test: V = 2169.78, P < 0.001) and log-
transformed (V = 30.79, P < 0.001) CRP data were originally
skewed, we categorized values into quartiles.
2.3. Depressive symptoms
Depressive symptoms were assessed using the eight-item ver-
sion of the Centre for Epidemiological Studies-Depression scale
(CES-D) which has comparable psychometric properties to the full
20-item CES-D (Turvey et al., 1999). Items captured information on
whether or not participants had experienced different symptoms
of depression, ‘‘much of the time” in the past week. Items were cat-
egorized according to a 3-factor solution (negative affect, anhedo-
nia, somatic) identified in an analysis of CES-D data across five
cohort studies (Carleton et al., 2013). We characterised items load-
ing on negative affect and anhedonia factors as assessing psycho-
logical symptoms, resulting in three somatic symptoms
(‘‘everything I did was an effort”, ‘‘sleep was restless” and ‘‘I could
not get going”) and five psychological symptoms (‘‘enjoyed life”,
‘‘felt depressed”, ‘‘happy”, ‘‘lonely”, ‘‘felt sad”).
2.4. Confounding variables
Information on self-reported physician-diagnoses of autoim-
mune and inflammatory disorders were recorded (diabetes,
rheumatoid arthritis, and coronary heart disease). The use of med-
ications with an anti-inflammatory effect (glucocorticoids and beta
blockers), antidepressants and body mass index (BMI) were
assessed during a visit to participants’ homes by nurses. Antide-
pressants, glucocorticoids and beta blockers were categorized
using the British National Formulary (BNF) 61 (‘‘British National
Formulary (BNF) 61 – March 2011”).
2.5. Statistical analysis
We used v2 test to examine differences in categorical variables.
Depressive symptoms were treated as dichotomous variables
(no = 0, yes = 1). We examined associations between quartiles of
CRP and individual CES-D items in separate logistic regression
models in which effect estimates were adjusted for sex, age, and
race/ethnicity, and the sum of the remaining items (to account
for the overlap between different depressive symptoms), autoim-
mune and inflammatory disorders, glucocorticoids and beta block-
ers (model 1). We then additionally adjusted for BMI (model 2). We
tested for a difference in the trend across quartiles of CRP usingPlease cite this article in press as: White, J., et al. Association of inflammation w
ple: The English Longitudinal Study of Ageing. Brain Behav. Immun. (2016), htorthogonal polynomial contrasts. We then included an interaction
term between quartiles of CRP and antidepressant treatment.
A sensitivity analysis using linear regression examined the asso-
ciation between CRP with the sum of the three items assessing
somatic symptoms, and also the sum of the five psychological
symptoms. All analyses were conducted using Stata 13.3. Results
3.1. Association between C-reactive protein and depressive symptoms
After adjusting for autoimmune disorders, inflammatory disor-
ders, and anti-inflammatory medication there was an independent,
dose-response association between quartiles of CRP and somatic
symptoms relating to everything being an effort (odds ratios
[ORs] of 1.20, 1.31, and 1.97 for the second, third, and fourth quar-
tiles of CRP respectively, compared with the first; P for
trend < 0.001), restless sleep (ORs of 1.11, 1.15, and 1.37; P for
trend = 0.002), and not being able to get going (ORs of 1.33, 1.40,
and 1.60; P for trend = 0.007). The association with negative affect
(‘‘felt depressed”) was also statistically significant (P for
trend = 0.03); but for other items relating to affect (sadness) and
anhedonia were not (Tables 1 and 2). Additional adjustment for
BMI partially attenuated estimates for restless sleep (ORs of 1.08,
1.11, and 1.30; P for trend = 0.002) and not being able to get going
(ORs of 1.28, 1.31, and 1.45; P for trend = 0.02).3.2. Association between C-reactive protein and depressive symptoms
stratified by antidepressant use
For the one in ten participants who took antidepressants
(10.6%), the association between CRP and all but the symptoms
of restless sleep (model 1: P = 0.03; model 2: P = 0.04) and feeling
depressed (P = 0.02) were not significant at conventional levels
(model 1: Tables S1 and S2). In contrast, among study members
not treated with antidepressants, there was an independent
dose-response association for somatic symptoms (Table S3). The
associations between CRP and restless sleep (P = 0.16) and not
being able to get going (P = 0.12) were attenuated after adjustment
for BMI, whereas the association for everything being an effort was
not (P < 0.001).
There was a non-significant association between quartiles of
CRP and psychological symptoms among those untreated with
antidepressants (Table S3), and an inverse association between
CRP and feeling depressed (P = 0.02). A significant interaction indi-
cated the dose-response trend was stronger in those untreated
than treated with antidepressants for the items relating to fati-
gue/low motivation – everything being an effort (P for a difference
in trend = 0.02) and restless sleep (P for a difference in trend = 0.04,
see Supplementary Fig. 1).3.3. Sensitivity analyses
People with missing data had fewer symptoms of depression
(P < 0.001), except restless sleep (P = 0.09); fewer reported baseline
heart disease (P = 0.005), diabetes, rheumatoid arthritis and used
antidepressants (P < 0.001); they had a lower body mass index
and level of CRP (P < 0.001), more took beta blockers (P = 0.03),
but no differences were found by age, sex, or the use of glucocor-
ticoids (P > 0.05). The pattern of attenuation for our main results
was replicated in models using the sum of the items assessing
somatic (Tables S5) or psychological symptoms (Tables S6).ith specific symptoms of depression in a general population of older peo-
tp://dx.doi.org/10.1016/j.bbi.2016.08.012
Table 1
Association between quartiles of C-reactive protein and ‘somatic’ depression symptoms in the ELSA cohort (N = 5909).
Outcome C-reactive protein (mg/L) Symptomatic, % (N) OR (95% CI)ab
Model 1 Model 2
Everything they did was an effort 0.10–0.79 11.6 (190) 1.00 (reference) 1.00 (reference)
0.80–1.60 14.9 (215) 1.20 (0.95, 1.52) 1.20 (0.94, 1.53)
1.61–3.30 16.2 (230) 1.31 (1.03, 1.65) 1.31 (1.03, 1.66)
3.31–157.50 24.4 (342) 1.97 (1.58, 2.47) 1.97 (1.56, 2.50)
P-trend <0.001 <0.001
Sleep was restless 0.10–0.79 29.5 (485) 1.00 (reference) 1.00 (reference)
0.80–1.60 32.6 (471) 1.11 (0.94, 1.30) 1.08 (0.91, 1.28)
1.61–3.30 33.8 (480) 1.15 (0.98, 1.35) 1.11 (0.94, 1.31)
3.31–157.50 40.4 (566) 1.37 (1.16, 1.60) 1.30 (1.09, 1.54)
P-trend 0.002 0.03
Could not get going much of the time 0.10–0.79 11.6 (190) 1.00 (reference) 1.00 (reference)
0.80–1.60 15.6 (226) 1.33 (1.06, 1.68) 1.28 (1.01, 1.62)
1.61–3.30 16.7 (238) 1.40 (1.11, 1.76) 1.31 (1.03, 1.66)
3.31–157.50 21.9 (307) 1.60 (1.27, 1.99) 1.45 (1.14, 1.84)
P-trend 0.007 0.02
a Model 1 adjusted for age, sex, race/ethnicity, and the sum of all the other depression symptoms besides the outcome symptom, autoimmune and inflammatory disorders:
diabetes, rheumatoid arthritis and heart disease; glucocorticoids and beta blockers. Glucocorticoids comprised of Prednisolone, Hydrocortisone, Deltacortril, and Budesonide.
Beta blockers comprised of Atenolol, Bisoprolol, Metoprolol, Propranolol Hydrochloride, and Labetalol Hydrochloride.
b Model 2 comprised model 1 plus body mass index.
Table 2
Association between Quartiles of C-reactive Protein and ‘Psychological’ Depression Symptoms in the ELSA cohort (N = 5909).
Outcome C-reactive protein (mg/L) Symptomatic, % (N) OR (95% CI)ab
Model 1 Model 2
Felt depressed much of the time 0.10–0.79 8.4 (138) 1.00 (reference) 1.00 (reference)
0.80–1.60 12.0 (174) 1.45 (1.11, 1.88) 1.44 (1.11, 1.88)
1.61–3.30 11.8 (168) 1.37 (1.05, 1.78) 1.36 (1.03, 1.78)
3.31–157.50 14.1 (197) 1.24 (0.96, 1.62) 1.23 (0.93, 1.63)
P-trend 0.03 0.04
Happy much of the time 0.10–0.79 91.5 (1502) 1.00 (reference) 1.00 (reference)
0.80–1.60 90.5 (1309) 1.02 (0.77, 1.34) 0.98 (0.74, 1.29)
1.61–3.30 90.9 (1290) 1.07 (0.81, 1.41) 1.00 (0.75, 1.33)
3.31–157.50 89.1 (1248) 1.16 (0.88, 1.53) 1.05 (0.78, 1.41)
P-trend 0.72 0.96
Lonely much of the time 0.10–0.79 9.1 (149) 1.00 (reference) 1.00 (reference)
0.80–1.60 9.3 (135) 0.89 (0.70, 1.16) 0.89 (0.69, 1.16)
1.61–3.30 10.2 (144) 0.92 (0.72, 1.19) 0.94 (0.72, 1.22)
3.31–157.50 13.6 (190) 1.05 (0.82, 1.34) 1.07 (0.82, 1.39)
P-trend 0.56 0.53
Enjoyed life much of the time 0.10–0.79 92.8 (1524) 1.00 (reference) 1.00 (reference)
0.80–1.60 91.9 (1330) 1.03 (0.77, 1.39) 0.97 (0.72, 1.31)
1.61–3.30 90.8 (1288) 0.87 (0.66, 1.16) 0.78 (0.58, 1.05)
3.31–157.50 89.8 (1258) 1.05 (0.79, 1.41) 0.90 (0.66, 1.22)
P-trend 0.57 0.36
Felt sad much of the time 0.10–0.79 15.8 (259) 1.00 (reference) 1.00 (reference)
0.80–1.60 17.1 (248) 0.99 (0.81, 1.22) 1.00 (0.81, 1.23)
1.61–3.30 16.2 (230) 0.87 (0.70, 1.07) 0.87 (0.70, 1.08)
3.31–157.50 19.1 (267) 0.83 (0.67, 1.03) 0.83 (0.66, 1.04)
P-trend 0.22 0.27
a Model 1 adjusted for age, sex, race/ethnicity, and the sum of all the other depression symptoms besides the outcome symptom, autoimmune and inflammatory disorders:
diabetes, rheumatoid arthritis and heart disease; glucocorticoids and beta blockers. Glucocorticoids comprised of Prednisolone, Hydrocortisone, Deltacortril, and Budesonide.
Beta blockers comprised of Atenolol, Bisoprolol, Metoprolol, Propranolol Hydrochloride, and Labetalol Hydrochloride.
b Model 2 comprised model 1 plus body mass index.
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We replicated the association between circulating CRP levels
and the somatic symptoms of fatigue, restless sleep, and low levels
of energy, in a representative community-based cohort of older
adults. Importantly, we only found this association to be present
in individuals who did not take antidepressants. This suggests that
antidepressants modify the association between CRP and the
somatic symptoms of depression, in particular symptoms related
to fatigue and low motivation.Please cite this article in press as: White, J., et al. Association of inflammation w
ple: The English Longitudinal Study of Ageing. Brain Behav. Immun. (2016), htThe graded association between CRP with restless sleep, fatigue
and low motivation was partially explained by differences in BMI.
This pattern of attenuation replicates that found in previous stud-
ies of CRP and the treatment for depression in elderly men
(Almeida et al., 2007) and depressive symptoms on the Patient
Health Questionnaire in US Army soldiers (Douglas et al., 2004).
Our results extend these findings to suggest that the attenuation
by BMI may be more relevant for somatic than psychological
symptoms. This attenuation could be due to confounding, whereby
BMI increases levels of CRP and somatic depressive symptoms.ith specific symptoms of depression in a general population of older peo-
tp://dx.doi.org/10.1016/j.bbi.2016.08.012
4 J. White et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxHowever, it is also possible that BMI mediates the influence of CRP
on somatic depressive symptoms, or that BMI influences CRP levels
which, in turn, induce depressive symptoms. No attenuation was
found for the CES-D item on ‘‘everything they did was an effort”
suggesting that this symptom is linked to CRP independently of
the effects of BMI.
Antidepressant use appeared to modify the association between
CRP and somatic symptoms. Antidepressants may exert part of
their effect through inhibition of inflammatory pathways
(Hannestad et al., 2011), which is consistent with a meta-
analysis showing inflammation is reduced after antidepressant
treatment among people with depression (O’Brien et al., 2006),
and two clinical trials showing decreases in interleukin-6 (Abbasi
et al., 2012) and CRP (Raison et al., 2013) were associated with
the treatment response from antidepressants.
Our study has a number of strengths. It is the first study to
examine the association between specific symptoms of depression
and CRP according to antidepressant use. That the pattern of
results we found closely replicates those from a US-based, younger
cohort (US NHANES mean age = 48 years) (Jokela et al., 2016) and
two population-based Danish studies (Wium-Andersen et al.,
2013), with different measures of depressive symptoms, supports
the generalizability of our findings. The main limitation of this
study is loss to follow-up, a perennial problem in longitudinal
studies. The eligibility criteria placed on participants to provide a
blood sample means those included may have been healthier than
the overall cohort. The smaller number of antidepressant users
meant we had less power in analyses for users than non-users. In
addition, the possibility of survivor bias is a concern with any study
of ageing, where fewer unhealthy participants with high levels of
CRP are available for analysis, such that the association with
depressive symptoms might be underestimated. To influence the
pattern of results we found, this bias would, however, have to
operate systematically according to antidepressant use.
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